Guided Therapeutics, Inc. announced that Dr. Gene Cartwright notified the Board of Directors of his intent to retire from his position as CEO of the Company and as a member of the Board, effective immediately. Mr. Cartwright's retirement was not the result of any disagreement with management or the Company on any matter relating to the Company's operations, policies or practices. On March 7, 2023, the Board appointed Dr. Mark Faupel, Ph.D., 67, the Company's Chief Operating Officer since December 2016, to replace Mr. Cartwright as the Company's President and Chief Executive Officer, effective as of March 6, 2023.

Dr. Faupel is one of the co-founders of the Company and he previously served as the Company's Chief Executive Officer from May 2007 through 2013. Dr. Faupel has also been a member of the Board since 2017. Dr. Faupel has more than 30 years of experience in developing non-invasive alternatives to surgical biopsies and blood tests, particularly in the area of cancer screening and diagnostics.

Dr. Faupel has served as a National Institutes of Health reviewer, is the inventor on several U.S. patents and has authored numerous scientific publications and presentations, appearing in such peer-reviewed journals as The Lancet. Dr. Faupel earned his Ph.D. in neuroanatomy and physiology from the University of Georgia. The Company believes Dr. Faupel is more than suitable to fulfill the roles of President and Chief Executive Officer of the Company because of his educational background and his extensive experience in several other executive roles within the Company.